Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cannabis Science, Inc. (OTC: CBIS).

Full DD Report for CBIS

You must become a subscriber to view this report.


Recent News from (OTC: CBIS)

Cannabis Benchmarks launches spot index to track wholesale pot prices
New Leaf Data Services unit Cannabis Benchmarks launches its Canada Cannabis Spot Index (CCSI) which will track the average wholesale price that an online or retail site pays for dried cannabis flower from licensed producers. More news on: Canopy Growth Corporation, Medical Marijuana, ...
Source: SeekingAlpha
Date: December, 18 2018 10:47
Congress passes farm bill, legalizes hemp production
Congress has backed a $867B farm bill . The House voted 386-47 in favor yesterday following an 87-13 thumbs up in the Senate the day before. President Trump is expected to sign it despite his preference for more stringent food stamp eligibility. More news on: Canopy Growth Corporation, Me...
Source: SeekingAlpha
Date: December, 13 2018 11:36
Cannabis Trends Have Medical Marijuana Stocks On Watch In 2019
CORAL GABLES, FL / ACCESSWIRE / December 13, 2018 / In the latest series of marijuana stock news the main focus has been on the 2018 US Farm Bill but what may be next is the focus on what is to come for 2019. David Goldstein, with the cannabis information company Potbotics, said 2018 wa...
Source: ACCESSWIRE IA
Date: December, 13 2018 10:45
New York recreational marijuana could come in 2019
New York Governor Andrew Cuomo will unveil a plan to legalize recreational marijuana in the state early next year, when Democrats have control of every branch of the state's government. More news on: Medical Marijuana, Inc., Aurora Cannabis Inc., GW Pharmaceuticals plc, News on ETFs, Con...
Source: SeekingAlpha
Date: December, 12 2018 02:45
No panic in marijuana sector over potential AG pick
Marijuana companies and analysts are mostly ambivalent about the report that William Barr could be picked to be the next U.S. Attorney General, according to Height Capital Markets. More news on: Medical Marijuana, Inc., Aurora Cannabis Inc., GW Pharmaceuticals plc, Consumer stocks news, He...
Source: SeekingAlpha
Date: December, 07 2018 09:04
Pot stocks set to rally after Altria $1.8B investment in Cronos Group
Cannabis companies are set for a bullish day after Cronos Group (NASDAQ: CRON ) announced a $1.8B investment from Altria Group. More news on: Cronos Group, Inc., Canopy Growth Corporation, Tilray, Inc., Healthcare stocks news, Consumer stocks news, Stocks on the move, Top stock market news...
Source: SeekingAlpha
Date: December, 07 2018 07:27
Lundbeck and Otsuka's combo treatment for PTSD successful in mid-stage study
Otsuka Pharmaceutical Company ( OTCPK:OTSKF )( OTCPK:OTSKY ) and development partner H. Lundbeck A/S ( OTC:HLUKF )( OTCPK:HLUYY ) announce positive results from a Phase 2 clinical trial evaluating the combination of brexpiprazole and Pfizer's ( PFE +0.7% ) Zoloft (sertraline HCl) for t...
Source: SeekingAlpha
Date: November, 30 2018 09:55
Rush for pot patents in full swing - Reuters
Reuters reports that the USPTO has issued 39 patents with "cannabis" or "marijuana" in their summaries, up from 29 last year and 14 in 2016. More news on: United Cannabis Corp., Canopy Growth Corporation, Medical Marijuana, Inc., Healthcare stocks news, Consumer stocks news, News on ETFs...
Source: SeekingAlpha
Date: November, 30 2018 08:44
Farm Bill advancing through Congress; legal hemp cultivation looming; shares up 29%
Nano cap Hemp ( OTCPK:HEMP +28.5% ) is up on triple normal volume in apparent reaction to its announcement that the U.S. 2018 Farm Bill is nearing the finish line, including a provision legalizing hemp cultivation, production and distribution. More news on: Hemp, Inc., Canopy Growth Co...
Source: SeekingAlpha
Date: November, 29 2018 15:24
Cannabis Penny Stocks: Cannabis Science, How Cheap is Too Cheap?
It is (predominantly) a red day on the cannabis penny stocks market. It’s always disappointing to see that! And it’s no different for one very small company by the name of Cannabis Science Inc. (OTC:CBIS) Cannabis Penny Stocks: CBIS Stock Investors have been clearly i...
Source: MicroSmallCap
Date: November, 27 2018 13:53

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-180.038350.0410.0440.0384,683,428
2018-12-170.041750.03850.04390.03810,085,676
2018-12-140.036750.0430.04330.03511,902,763
2018-12-130.03870.0370.03990.0377,543,989
2018-12-120.034050.038640.0390.032111,668,767

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-173,021,15910,085,67629.9549Cover
2018-12-143,587,05611,902,76330.1363Cover
2018-12-133,773,3027,543,98950.0173Short
2018-12-126,115,62111,638,76752.5453Short
2018-12-111,542,7673,253,45747.4193Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CBIS.


About Cannabis Science, Inc. (OTC: CBIS)

Logo for Cannabis Science, Inc. (OTC: CBIS)

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS S/BCC , CS TATI , and CS NEURO , respectively.

 

 

 

Current Management

  • Raymond Dabney / President, CEO, CoFounder
    • Mr. Raymond C. Dabney, President amp CEO, CoFounder Mr. Dabney brings years of experience in corporate finance, corporate structure, corporate communications, sales and marketing for public companies. Mr. Dabney has significant experience in public and private venture capital, early stage equity/debt financings and regulatory compliance. Mr. Dabney has cofounded several public and private companies in many diverse industries such as drug development, entertainment, media, advertising, mining, automobile, hightech, manufacturing, real estate and communications, many of which he launched from day one. Cannabis Science is a prime example of the type of organizations that Mr. Dabney has built from inception. Mr. Dabney has extensive international relationships that he has utilized to grow each Company, from the US, Canada, several European centers, such as Paris, London, Amsterdam and eastern Spain, as well as countries in the West Indies, South America, and Asia. Mr. Dabney s niche market knowledge, team leadership, and management style facilitate the continued growth and forward thinking that successfully bring his projects from concept to completion.
  • Benjamin Tam / Secretary, CFO
  • Robert Kane / COO
    • Chief Financial Officer and Director Mr. Kane wrote his first business plan in . In , he was hired at Ryan, Beck, and Company, which was bought by the yearold, top ten, financial firm Stifel Nicolaus NYSE: SF as a registered representative. On December , , Mr. Kane walked away from the financial markets and started his own firm, Robert Kane Partners, which specializes in business and management planning, investor presentations, and investor relations. Mr. Kane held the position of Director of Investor Relations for Medical Marijuana, Inc., the first ever publicly traded medical marijuana company. He also held the position of Chief Financial Officer for Cannabiz Business University. Robert Kane s mission is transforming and leading the Medical Cannabis Industry into a viable investment alternative for all types of investors.
  • Raymond Dabney / Chairman
    • Mr. Raymond C. Dabney, President amp CEO, CoFounder Mr. Dabney brings years of experience in corporate finance, corporate structure, corporate communications, sales and marketing for public companies. Mr. Dabney has significant experience in public and private venture capital, early stage equity/debt financings and regulatory compliance. Mr. Dabney has cofounded several public and private companies in many diverse industries such as drug development, entertainment, media, advertising, mining, automobile, hightech, manufacturing, real estate and communications, many of which he launched from day one. Cannabis Science is a prime example of the type of organizations that Mr. Dabney has built from inception. Mr. Dabney has extensive international relationships that he has utilized to grow each Company, from the US, Canada, several European centers, such as Paris, London, Amsterdam and eastern Spain, as well as countries in the West Indies, South America, and Asia. Mr. Dabney s niche market knowledge, team leadership, and management style facilitate the continued growth and forward thinking that successfully bring his projects from concept to completion.
  • Robert Kane / Director
    • Chief Financial Officer and Director Mr. Kane wrote his first business plan in . In , he was hired at Ryan, Beck, and Company, which was bought by the yearold, top ten, financial firm Stifel Nicolaus NYSE: SF as a registered representative. On December , , Mr. Kane walked away from the financial markets and started his own firm, Robert Kane Partners, which specializes in business and management planning, investor presentations, and investor relations. Mr. Kane held the position of Director of Investor Relations for Medical Marijuana, Inc., the first ever publicly traded medical marijuana company. He also held the position of Chief Financial Officer for Cannabiz Business University. Robert Kane s mission is transforming and leading the Medical Cannabis Industry into a viable investment alternative for all types of investors.
  • Benjamin Tam /

Current Share Structure

  • Market Cap: $143,411,458 - 05/11/2018
  • Issue and Outstanding: 2,551,805,296 - 10/16/2017
  • Float: 24,000,000 - 06/17/2010

 


Recent Filings from (OTC: CBIS)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 16 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 11 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 20 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 15 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 31 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 30 2017

 

 


Daily Technical Chart for (OTC: CBIS)

Daily Technical Chart for (OTC: CBIS)


Stay tuned for daily updates and more on (OTC: CBIS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CBIS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CBIS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CBIS and does not buy, sell, or trade any shares of CBIS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/